ambr® 250 Modular Bioreactor System Released by Sartorius Stedim Biotech
- Company Details
- Products & Services
- White Papers
- Press Releases
- Regional Offices
- Contact Company
ambr® 250 Modular Bioreactor System Released by Sartorius Stedim BiotechSartorius
The amblr® 250 modular bioreactor system is an expandable benchtop workstation, which offers a simple approach to process development for fermentation and cell culture.
Sartorius Stedim Biotech (SSB) introduced the ambr® 250 modular to offer bioprocess scientists access to advanced benchtop bioreactor technology for process development. This system combines a unique single-use bioreactor vessel and consists of a workstation with 2, 4, 6, or 8 single-use bioreactors, with a working volume range of 100mL to 250mL.
These mini bioreactors are based on the same stirred tank bioreactors in the well-established ambr® 250 high-throughput system and contain impellers suitable for fermentation or cell culture. They are also fully integrated with liquid reservoirs and syringe pumps, allowing rapid experimental set up and turn around, significantly increasing lab efficiency.
The system brings simplicity to the lab bench. By following three easy steps, a bioreactor and all required accessories can be connected in a couple of minutes. Once installed, the bioreactor has all the required process services for parameter control, including pH, temperature, or agitation.
In addition, feeds can now be delivered with high-accuracy from the reagent reservoirs via the syringe pumps into the bioreactor. One control unit is capable to manage up to eight bioreactor stations independently via an easy-to-use touchscreen user interface.
Product Manager at SSB Mwai Ngibuini states: "Our new ambr® 250 modular provides an excellent single-use platform, which enables rapid process development and optimisation for scale-up to larger bioreactors such as BIOSTAT® pilot and manufacturing scale bioreactors.
Utilising this single-use workflow will allow bioprocess scientists to improve productivity in their scalable bioprocess development and reduce development time-lines; ensuring production of industrial enzymes, biologics and vaccines is more cost-efficient."
There will be two live webinars on Tuesday July 19 to introduce the new product and present data on system performance and applications.